AII vs BRK-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AII exhibits strong profitability and growth fundamentals, supported by a high Piotroski F-Score of 4 (stable), though the absence of an Altman Z-Score raises caution regarding long-term financial distress risk. The stock trades at a deeply discounted valuation relative to its intrinsic value, with a current price of $19.08 versus a Graham Number of $46.53 and an intrinsic value estimate of $164.91, suggesting significant undervaluation. Exceptional earnings growth (70.1% YoY, 148.5% Q/Q) and consistent earnings beats (70.58% average surprise) reinforce confidence in future performance. However, bearish insider activity and a lack of dividend yield introduce some caution despite strong technical momentum and analyst buy sentiment.
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Compare Another Pair
Related Comparisons
AII vs BRK-B: Head-to-Head Comparison
This page compares American Integrity Insurance Group, Inc. (AII) and Berkshire Hathaway Inc. (BRK-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.